Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
8(32%)
Results Posted
50%(1 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_2
12
48%
Ph phase_3
8
32%
Ph phase_1
5
20%

Phase Distribution

5

Early Stage

12

Mid Stage

8

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
5(20.0%)
Phase 2Efficacy & side effects
12(48.0%)
Phase 3Large-scale testing
8(32.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

8

trials recruiting

Total Trials

25

all time

Status Distribution
Active(12)
Completed(2)
Terminated(3)
Other(8)

Detailed Status

unknown8
Recruiting6
Not yet recruiting4
Completed2
Withdrawn2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
25
Active
8
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (20.0%)
Phase 212 (48.0%)
Phase 38 (32.0%)

Trials by Status

completed28%
unknown832%
withdrawn28%
active_not_recruiting28%
not_yet_recruiting416%
recruiting624%
terminated14%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT07507916Phase 2

Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting
NCT07457528Phase 2

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Recruiting
NCT07113275Phase 3

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT05353257Phase 3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active Not Recruiting
NCT04063163Phase 3

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

Completed
NCT06115642Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Recruiting
NCT06349980Phase 2

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting
NCT04547166Phase 2

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Recruiting
NCT05584137Phase 2

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

Terminated
NCT05513573Phase 2

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Active Not Recruiting
NCT05443646Phase 2

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Recruiting
NCT05400265Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Completed
NCT04033354Phase 3

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Unknown
NCT04297995Phase 2

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Unknown
NCT03941574Phase 2

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Recruiting
NCT05442996Phase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Unknown
NCT04139135Phase 3

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Unknown
NCT04465734Phase 3

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Withdrawn
NCT04806945Phase 3

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Withdrawn
NCT05354700Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
25